Table 1. Summary tables of prospective/retrospective series in nccRCC.

Study name or first author	Drug/s	N	Line of treatment	Type of study	ORR	PFS	OS
ASPEN	Everolimus vs. Sunitinib	108	First	Prospective	Everolimus =8%; Sunitinib =18%	Everolimus =5.6 months (5.5–60); Sunitinib =8.3 (5.8–11.4)	Everolimus =13.2 (9.7–37.9); Sunitinib =31.5 (14.8–NA)
ESPN	Everolimus vs. Sunitinib	68	First/Second	Prospective	Everolimus =3%; Sunitinib =11%	Everolimus =4.1 months (2.7–10.5); Sunitinib =6.1 (4.2–9.4)	Everolimus =14.9 (8.0–23.4); Sunitinib =16.2 (14.2–NA)
RECORD 3	Everolimus vs. Sunitinib	66	First/Second	Prospective	NR	Everolimus =5.1 months (2.6–7.9); Sunitinib =7.2 (5.4–13.8)	NR
NCT00726323	Foretinib	74	First/Second	Prospective	13.5%	9.3 months (6.9–12.9)	Not reached
NCT02127710	Savolitinib	109	First	Prospective	18% (in MET +)	MET+ =6.2 months (4.1–7.0)	NR
ARCC NCT00065468	INF vs. Temsirolimus	73	First	Prospective	INF =12%; Temsirolimus =12%	INF=1.8 (1.6–2.1); Temsirolimus=7.0 (3.9–8.9)	INF =4.3 (3.2–7.3); Temsirolimus =11.6 (8.9–13)
RAPTOR	Everolimus	88	First	Prospective	1%	pRCC type I =7.9 (2.1–11); pRCC type II =5.1 (3.3–5.5)	pRCC type I =28.0 (7.6–NA); pRCC type II =24.2 (15.8–32.8)
SUPAP	Sunitinib	61	First	Prospective	NR	pRCC type I =6.6 (2.8–14.8); pRCC type II =5.5 (3.8–7.1)	pRCC type I =17.8 (5.7–26.1); pRCC type II =12.4 (8.4–14.3)
NCT01798446	Axitinib	40	Second/Third	Prospective	37.5%	7.4 months (5.2–9.5)	12.1 months (6.4–17.7)
Martínez Chanzá N	Cabozantinib	112	All	Retrospective	27%	Time to treatment failure: 6.7 months (5.5–8.6)	12 months OS 51% (39–62%)
Pisciandaro M	Cabozantinib	17	All	Retrospective	35%	7.83 months (0.4–13.4)	12 months OS: 60%
Matthew T. Campbell	Cabozantinib	30	All	Retrospective	14.3%	8.6 months (6.1–14.7)	25.4 months (11.4–28.8)
De Giorgi U.	Nivolumab	35	All	Retrospective	19.3%	NR	NR
Koshkin Vadim S	Nivolumab	41	All	Retrospective	20%	3.5 months	Not reached

NR, not reported; OS, overall survival; PFS, progression free survival; ORR, objective response rate; N, number of patients.